QL325 is a T cell engager targeting CLEC12A on AML blasts. In healthy individuals, CLEC12A expression is limited to monocytes and CD34+CD38- progenitor cells. In vitro, QL325 activated T cells in a CLEC12A-dependent manner and redirected T cells to kill CLEC12A-positive AML cancer cells. QL325 suppressed the growth of AML tumors in multiple xenograft models, including ones that are resistant to venetoclax. A phase 1 clinical trial is ongoing to evaluate the safety and early efficacy of QL325 in patients with refractory or relapsed AML.
Preclinical data will be presented at the AACR Annual Meeting 2024 in San Diego.